CEO, Anders Månsson will be at the Nordic Life Science Days in Copenhagen
Onc File published (year): 2023
CEO, Anders Månsson and CFO, Tore Kvam will present Oncoinvent to investors during the JP Morgan 42nd Annual Healthcare Conference
CEO, Anders Månsson will present Oncoinvent at the DNB Nordic Healthcare Conference 2023
Oncoinvent will be presenting the company at the Nordic American Healthcare Conference 2023. The company will be represented by CEO Anders Månsson and CFO Tore Kvam
Progressing to study Radspherin® in the first-line treatment setting for ovarian cancer
IND clearance is now obtained for both lead indications for Radspherin®
This marks the first IND clearance for initiation of Radspherin® clinical trials in the US
Oncoinvent would like to extend an invitation to a short update on the company and a presentation on Q3 report including outlook. The presentation will be held on Thursday 23. November 2023 at 10:00 AM in the offices of Carnegie, Fjordalléen 16, Oslo, 5. floor, Meeting room: Verftet. It will also be possible to attend … Read more
CEO, Anders Månsson and CFO, Tore Kvam presented Oncoinvent at the Radforsk’s podcast Radium episode 284. The podcast can be heard HERE (norwegian)
CEO, Anders Månsson presentes Oncoinvent at the LSX conference and meet with investors.
At 18 months, no patients at the recommended dose of 7 MBq experienced peritoneal recurrences
Robust safety profile demonstrated, no serious adverse events related to Radspherin® reported
Presentation on October 4, 2023, at 11:55 a.m. CET (5:55 a.m. EDT)